Saturday, November 23, 2024
Facebook Linkedin Twitter
HomeTagsTardive Dyskinesia

Tardive Dyskinesia

Biotechnology

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

News Desk -
Neurocrine Biosciences, Inc announced the launch of a new sprinkle formulation of INGREZZA capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the...
Biotechnology

Neurocrine Biosciences Announces Regulatory Approval of Dysval (valbenazine) for the Treatment of Tardive Dyskinesia in Japan

PR Newswire -
Neurocrine Biosciences, Inc. announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us